Registry of Lobbyists
| Subject matters | Details | Categories |
|---|---|---|
|
Health, Industry, Internal Trade, International Trade, Justice and Law Enforcement
|
Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs
|
Policies or Program
|
|
Economic Development, Government Procurement, Health, Industry, International Development, International Relations, International Trade, Justice and Law Enforcement, Regional Development, Research and Development
|
Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease
|
Policies or Program
|
|
Consumer Issues, Health, Industry, Justice and Law Enforcement
|
Canada's Food and Consumer Safety Action Plan as it relates to the regulation and protection of biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Intellectual Property, International Relations, International Trade
|
Canada-United States Regulatory Cooperation Council (RCC) initiatives related to the regulation of biopharmaceutical products
|
Policies or Program
|
|
Environment, Health, Science and Technology
|
Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies
|
Legislative Proposal, Bill or Resolution, Regulation
|
|
Economic Development, Health, Industry, Intellectual Property, Natural Resources, Science and Technology
|
Canadian Institutes of Health Research (CIHR) Clinical Research Initiative as it relates to public/private research and development partnerships
|
Policies or Program
|
|
Consumer Issues, Federal-Provincial Relations, Health, Industry, Intellectual Property, Science and Technology
|
Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework
|
Policies or Program
|
|
Federal-Provincial Relations, Health, Industry, Intellectual Property, Science and Technology
|
Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH)
|
Policies or Program
|
|
Consumer Issues, Health, Industry, Intellectual Property, Research and Development
|
Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products
|
Regulation
|
|
Health, Industry, Intellectual Property, International Relations, International Trade
|
Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals
|
Regulation, Legislative Proposal, Bill or Resolution
|
|
Foreign Affairs, Health, Industry, Intellectual Property, International Relations, International Trade, Taxation and Finance
|
Free trade treaty agreement as they relate to The Canada-United States-Mexico Agreement (CUSMA) and free trade negotiations as it relates to India, the European Union, Japan, MERCOSUR and the Trans-Pacific Partnership
|
Policies or Program
|
|
Consumer Issues, Health, Industry, Intellectual Property, Research and Development
|
Health Canada's Regulatory Roadmap for Health Products and Food as it relates to the biopharmaceutical industry
|
Regulation
|
|
Health, Industry
|
Health Canada’s Interim Orders relating to COVID-19: The Interim Order Respecting Drugs, Medical Devices and Foods for a Special Dietary Purpose in Relation to COVID-19; The Interim Order Respecting Clinical Trials for Medical Devices and Drugs Relating to COVID-19; The Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19; The Interim Order Respecting the Prevention and Alleviation of Shortages of Drugs in Relation to Covid-19
|
Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Intellectual Property
|
New Substances Notification Regulations as it relates to the biopharmaceutical industry
|
Regulation
|
|
Health, Industry, Intellectual Property, Internal Trade, Research and Development, Taxation and Finance
|
Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products
|
Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Intellectual Property, Research and Development, Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products
|
Regulation
|
|
Health, Industry, Intellectual Property, International Development, International Relations, International Trade, Taxation and Finance
|
Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive
|
Regulation
|
|
Health, Industry, Intellectual Property
|
Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products
|
Regulation
|
|
Consumer Issues, Health, Industry, Intellectual Property, International Development, International Relations, International Trade, Taxation and Finance
|
Pharmaceutical pricing policy issues arising from the jurisdiction of the Patented Medicines Prices Review Board (PMPRB)
|
Policies or Program
|
|
Constitutional Issues, Consumer Issues, Federal-Provincial Relations, Government Procurement, Health, Industry
|
Proposed pharmacare legislation related to any future national pharmacare program
|
Legislative Proposal, Bill or Resolution
|
|
Health, Industry, Research and Development, Taxation and Finance
|
Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits
|
Policies or Program
|
|
Health, Industry
|
Smart Regulations as it relates to the biopharmaceutical industry
|
Regulation
|
|
Health, Industry, Intellectual Property, Natural Resources, Research and Development, Science and Technology
|
Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations
|
Policies or Program
|
|
Health, Industry, Natural Resources, Science and Technology
|
The government's Science and Technology strategy as it relates to the biopharmaceutical industry
|
Policies or Program
|
|
Health, Industry, Intellectual Property, International Development, International Relations, International Trade
|
World Health Organization (WHO) issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernmental Working Group (IGWG) World Intellectual Property Organization (WIPO) issues concerning the protection of and access to intellectual property
|
Policies or Program
|
|
Health, Industry, Intellectual Property, International Development, International Relations, International Trade
|
World Trade Organization (WTO) issues concerning the agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility"
|
Policies or Program
|
Address:
55 Metcalfe Street, Suite 1220
Ottawa, ON K1P 6L5
Canada
Telephone number:
613-236-0455
Web address:
http://innovativemedicines.ca/
David Renwick, Interim President
Innovative Medicines Canada is not a subsidiary of any other parent companies.
Innovative Medicines Canada is not a coalition.
The activities of Innovative Medicines Canada are not controlled or directed by another individual, organization or corporation with a direct interest in the outcome of this undertaking.
Innovative Medicines Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
John Delacourt | Public offices held
Firm: Counsel Public Affairs